Ylitalo P, Vapaatalo H
Arzneimittelforschung. 1977;27(9):1726-8.
The urinary crystallization of N1-pyrimid-2-yl-sulfanilamide (sulphadiazine, Sulfolex) during treatment with a small therapeutic dose (600 mg/day p.o.) for 6 days was evaluated in seven voluntary female subjects. In 5/7 and 3/7, respectively, of the urine supernatants obtained from samples collected 6 and 24 h after the last dose of sulphadiazine, the sulphonamide concentration exceeded the experimental solubility of the drug in 37 degrees C urine at the same pH. However, only in 3 sediments of the 6-h urine samples could a few sulphadiazine crystals be found. The findings suggest that the urine often can be oversaturated in respect to sulphadiazine, without any marked crystallization.
在7名自愿参与的女性受试者中,评估了小治疗剂量(口服600毫克/天)磺胺嘧啶(N1-嘧啶-2-基-磺胺,Sulfolex)治疗6天时的尿结晶情况。在末次服用磺胺嘧啶后6小时和24小时采集的尿液样本的上清液中,磺胺浓度分别在5/7和3/7的样本中超过了该药物在相同pH值的37℃尿液中的实验溶解度。然而,仅在6小时尿液样本的3份沉淀物中发现了少量磺胺嘧啶晶体。这些发现表明,尿液中磺胺嘧啶常常会过饱和,但无明显结晶。